ImmuneOnco Announced Appointment of Dr. Xiaodong Gan as Senior Vice President for Clinical trials

On April 1, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced the appointment of Gan, Xiaodong as the senior vice president , mainly responsible for clinical trial affairs in the United States. ......

2022-04-01

ImmuneOnco Announced Appointment of Dr. Xu, Wencheng as Vice President of Clinical Operations

On March 30, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced the appointment of Dr. Xu, Wencheng as the vice president of clinical operations. After graduating from the Departmen......

2022-03-30

Invention patent of IMM0306 was authorized by the US Patent Office

On March 29, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") declared that the bispecific antibody drug targeting both CD47 and CD20 (Project No.: IMM0306) was authorized by the US Patent Office (APPLICAT......

2022-03-29

ImmuneOnco will share data in two posters at 2022 Annual Meeting of American Association for Cancer Research（AACR）

On March 28, 2022, ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. (hereinafter referred to as "ImmuneOnco") announced that data from 2 different new projects in two posters will be presented at the 2022 annual meeting of American Association for Cance......

2022-03-28

ImmuneOnco: IMM2520 invention patent was authorized by Japan Patent Office

On March 22, 2022, the bispecific antibody drug candidate (project number: IMM2520) independently developed by ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd. that targets both CD47 and PD-L1 was authorized by the Japanese Patent Office (Japanese Paten......

2022-03-23